



**Prior Authorization Approval Criteria**  
*Department of Pharmacy Services*

**Generic Name:** Lisdexamfetamine Dimesylate

**Brand Name:** Vyvanse

**Medication Class:** Stimulant

**FDA Approved Uses:** Treatment of Attention- Deficit/Hyperactivity Disorder (ADHD)

**Available Dosage Forms:** 20mg, 30 mg, 40mg, 50 mg, 60mg and 70 mg Capsules

**Usual Dose:** 30 mg -70 mg once daily

**Duration of Therapy:** To be determined by physician

**Approximate monthly cost** (based on AWP 2008): 20mg, 30mg, 40mg, 50mg, 60mg or 70mg once daily is about \$136.80/month.

**Criteria for Use:** *(bullet points below are all inclusive unless otherwise noted)*

- Clinically diagnose ADHD.
- Must be older than 6 years of age.
- Tried and failed long acting methylphenidate.
- Tried and failed long acting amphetamine mixed salts
- Tried and failed dextroamphetamine

**Contraindications:**

- Advanced arteriosclerosis, symptomatic cardiovascular disease, and moderate to severe hypertension.
- Hyperthyroidism
- known hypersensitivity or idiosyncrasy to the sympathomimetic amines,
- Glaucoma
- Agitated states
- Patients with a history of drug abuse
- Administration during or within 14 days following the administration of monoamine oxidase inhibitors.

**Not Approved if:**

- Does not meet the above stated criteria.
- Have any contraindications to the use of Vyvanse.



**Special Considerations:**

- Lisdexamfetamine dimesylate is a pro-drug in which d-amphetamine is covalently bonded to L-lysine.
- Designed to have less potential than amphetamine for abuse, diversion or overdose toxicity.
- Lisdexamfetamine is a Schedule II controlled substance.
- There is no evidence that lisdexamfetamine dimesylate offers an advantage over any other formulation of amphetamine for treatment of children with ADHD.

P&T Approval: \_\_\_\_\_ Date: \_\_\_\_\_